NCT07567742
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 19 words
- Start date changed from estimate of May 6, 2026 to May 8, 2026
- Secondary endpoints: details revised at 5 of 8 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Severe Radiation-Induced Oral Mucositis
Timeframe: From the start of radiotherapy to 4 weeks after completion of radiotherapy
Secondary (8)
Onset Time of Severe Radiation-Induced Oral Mucositis
Duration of Severe Radiation-Induced Oral Mucositis
Recovery Rate of Severe Radiation-Induced Oral Mucositis
Incidence of Radiation-Induced Oral Mucositis
Incidence of Radiotherapy Interruption
Show 3 moreShow less
Quality of life (QoL)
Numeric Rating Scale for Pain
Safety as Assessed by CTCAE
Arms and interventions
TaurineExperimental
Oral taurine 1 g twice daily, starting 3 days before radiotherapy until 1 week after completion of radiotherapy, plus standard of care for RIOM.
ControlNo intervention
Patients in the control arm will receive the standard of care for RIOM.
Drugs: Taurine
Sites
1 site in 1 country
- Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, China